Patents by Inventor Lee A. Flippin

Lee A. Flippin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20130310565
    Abstract: The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.
    Type: Application
    Filed: June 7, 2013
    Publication date: November 21, 2013
    Inventors: Michael P. Arend, Lee A. Flippin, Volkmar Guenzler-Pukall, Wen-Bin Ho, Eric D. Turtle, Xiaohui Du
  • Stabilization of Hypoxia Inducible Factor (HIF) Alpha
    Publication number: 20130245037
    Abstract: The present invention relates to methods of stabilizing the alpha subunit of hypoxia inducible factor (HIF). The invention further relates to methods of preventing, pretreating, or treating conditions associated with HIF, including ischemic and hypoxic conditions. Compounds for use in these methods are also provided.
    Type: Application
    Filed: May 17, 2013
    Publication date: September 19, 2013
    Applicant: FibroGen, Inc.
    Inventors: Volkmar Guenzler-Pukall, Thomas B. Neff, Qingjian Wang, Michael P. Arend, Lee A. Flippin, Alex Melekhov
  • Methods for treating anemia using inhibitors of hypoxia-inducible factor (HIF) hydroxylase
    Publication number: 20130203805
    Abstract: The present invention relates to methods for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo. Methods for treating, pretreating or preconditioning, or preventing erythropoietin-associated conditions are also included. Compounds for use in these methods are provided, as are methods of identifying such compounds.
    Type: Application
    Filed: September 13, 2012
    Publication date: August 8, 2013
    Applicant: FIBROGEN, INC.
    Inventors: Stephen J. Klaus, Al Y. Lin, Thomas B. Neff, Qingjian Wang, Volkmar Guenzler-Pukall, Michael P. Arend, Lee A. Flippin, Alex Melekhov
  • NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20130178417
    Abstract: The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.
    Type: Application
    Filed: August 30, 2012
    Publication date: July 11, 2013
    Inventors: Michael P. AREND, Lee A. FLIPPIN, Volkmar GUENZLER-PUKALL, Wen-Bin HO, Eric D. TURTLE, Xiaohui DU
  • Stabilization of hypoxia inducible factor (HIF) alpha
    Patent number: 8466172
    Abstract: The present invention relates to methods of stabilizing the alpha subunit of hypoxia inducible factor (HIF). The invention further relates to methods of preventing, pretreating, or treating conditions associated with HIF, including ischemic and hypoxic conditions. Compounds for use in these methods are also provided.
    Type: Grant
    Filed: December 2, 2010
    Date of Patent: June 18, 2013
    Assignee: FibroGen, Inc.
    Inventors: Volkmar Guenzler-Pukall, Thomas B. Neff, Qingjian Wang, Michael P. Arend, Lee A. Flippin, Alex Melekhov
  • Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors
    Patent number: 8324405
    Abstract: The present invention relates to novel compounds of formula (I), methods, and compositions capable of decreasing HIF hydroxylase activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF).
    Type: Grant
    Filed: February 5, 2009
    Date of Patent: December 4, 2012
    Assignee: FibroGen, Inc.
    Inventors: Wen-bin Ho, Lee Wright, Shaojiang Deng, Eric Turtle, Lee A. Flippin
  • Nitrogen-containing heteroaryl compounds and methods of use thereof
    Patent number: 8278325
    Abstract: The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.
    Type: Grant
    Filed: July 19, 2011
    Date of Patent: October 2, 2012
    Assignee: FibroGen, Inc.
    Inventors: Michael P. Arend, Lee A. Flippin, Volkmar Guenzler-Pukall, Wen-Bin Ho, Eric Turtle, Xiaohui Du
  • Oxazolopyridine and isoxazolopyridine derivatives for use in the treatment of HIF-mediated conditions
    Patent number: 8269008
    Abstract: The present invention relates to novel compounds capable of modulating the stability and/or activity of hypoxia inducible factor (HIF) by inhibiting the activity of at least one HIF hydroxylase enzyme.
    Type: Grant
    Filed: December 2, 2008
    Date of Patent: September 18, 2012
    Assignee: FibroGen, Inc.
    Inventors: Michael P. Arend, Heng Cheng, Lee A. Flippin, Danny Ng, Eric D. Turtle, Min Wu
  • CYANOISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20120178755
    Abstract: The present invention relates to cyanoisoquinoline compounds suitable for use in treating hypoxia inducible factor-mediated and/or erythropoietin-associated conditions.
    Type: Application
    Filed: March 26, 2012
    Publication date: July 12, 2012
    Inventors: Michael Arend, Lee A. Flippin, Min Wu, Eric D. Turtle, Wen-Bin Ho, Shaojiang Deng
  • Compounds and methods for their use
    Patent number: 8217043
    Abstract: The present invention relates to novel compounds capable of modulating the stability and/or activity of hypoxia inducible factor (HIF) by inhibiting the activity of at least one HIF hydroxylase enzyme.
    Type: Grant
    Filed: August 20, 2009
    Date of Patent: July 10, 2012
    Assignee: Fibrogen, Inc.
    Inventors: Shaojiang Deng, Wen-Bin Ho, Lee A. Flippin
  • NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20120029011
    Abstract: The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.
    Type: Application
    Filed: July 19, 2011
    Publication date: February 2, 2012
    Inventors: Michael P. Arend, Lee A. Flippin, Volkmar Guenzler-Pukall, Wen-Bin Ho, Eric D. Turtle, Xiaohui Du
  • THIOCHROMENE DERIVATIVES AS HIF HYDROXYLASE INHIBITORS
    Publication number: 20110305776
    Abstract: The present invention relates to novel compounds, methods, and compositions capable of decreasing HIF hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF).
    Type: Application
    Filed: November 11, 2009
    Publication date: December 15, 2011
    Applicant: FibroGen, Inc.
    Inventors: Wen-Bin Ho, Lee A. Flippin, Craig Mossman, Eric D. Turtle, Lee R. Wright
  • Nitrogen-containing heteroaryl compounds and methods of use thereof
    Patent number: 8017625
    Abstract: The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.
    Type: Grant
    Filed: January 16, 2008
    Date of Patent: September 13, 2011
    Assignee: Fibrogen, Inc.
    Inventors: Michael P. Arend, Lee A. Flippin, Volkmar Guenzler-Pukall, Web-Bin Ho, Eric Turtle, Xiaohui Du
  • Cyanoisoquinoline Compounds and Methods of Use Thereof
    Publication number: 20110212959
    Abstract: The present invention relates to cyanoisoquinoline compounds suitable for use in treating hypoxia inducible factor-mediated and/or erythropoietin-associated conditions.
    Type: Application
    Filed: March 7, 2011
    Publication date: September 1, 2011
    Inventors: Michael P. Arend, Lee A. Flippin, Min Wu, Eric D. Turtle, Wen-Bin Ho, Shaojiang Deng
  • Methods for treating anemia using inhibitors of hypoxia-inducible factor (HIF) hydroxylase
    Publication number: 20110166178
    Abstract: The present invention relates to methods for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo. Methods for treating, pretreating or preconditioning, or preventing erythropoietin-associated conditions are also included. Compounds for use in these methods are provided, as are methods of identifying such compounds.
    Type: Application
    Filed: February 17, 2011
    Publication date: July 7, 2011
    Applicant: FibroGen, Inc.
    Inventors: Stephen J. Klaus, Al Y. Lin, Thoams B. Neff, Qingjian Wang, Volkmar Guenzler-Pukall, Michael P. Arend, Lee A. Flippin, Alex Melekhov
  • Stabilization of hypoxia inducible factor (HIF) alpha
    Publication number: 20110166145
    Abstract: The present invention relates to methods of stabilizing the alpha subunit of hypoxia inducible factor (HIF). The invention further relates to methods of preventing, pretreating, or treating conditions associated with HIF, including ischemic and hypoxic conditions. Compounds for use in these methods are also provided.
    Type: Application
    Filed: December 2, 2010
    Publication date: July 7, 2011
    Applicant: FibroGen, Inc.
    Inventors: Volkmar Guenzler-Pukall, Thomas B. Neff, Qingjian Wang, Michael P. Arend, Lee A. Flippin, Alex Melekhov
  • Cyanoisoquinoline compounds and methods of use thereof
    Patent number: 7928120
    Abstract: The present invention relates to cyanoisoquinoline compounds suitable for use in treating hypoxia inducible factor-mediated and/or erythropoietin-associated conditions.
    Type: Grant
    Filed: January 26, 2007
    Date of Patent: April 19, 2011
    Assignee: FibroGen, Inc.
    Inventors: Michael Arend, Lee A. Flippin, Min Wu, Eric D. Turtle, Wen-Bin Ho, Shaojiang Deng
  • Nitrogen-containing heteroaryl compounds and methods of use thereof
    Patent number: 7863292
    Abstract: The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.
    Type: Grant
    Filed: January 19, 2007
    Date of Patent: January 4, 2011
    Assignee: FibroGen, Inc.
    Inventors: Michael P. Arend, Lee A. Flippin, Volkmar Guenzler-Pukall, Wen-Bin Ho, Eric Turtle, Xiaohui Du
  • ISOTHIAZOLE-PYRIDINE DERIVATES AS MODULATORS OF HIF (HYPOXIA INDUCIBLE FACTOR) ACTIVITY
    Publication number: 20100330199
    Abstract: The present invention relates to novel compounds according to Formula I or II, methods, and compositions capable of decreasing HIF hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF). Formula (I) or (II).
    Type: Application
    Filed: January 12, 2009
    Publication date: December 30, 2010
    Inventors: Xiaoti Zhou, Michael P. Arend, Min Wu, Lee A. Flippin
  • CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS
    Publication number: 20100331400
    Abstract: The present invention relates to novel compounds of formula (I), methods, and compositions capable of decreasing HIF hydroxylase activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF).
    Type: Application
    Filed: February 5, 2009
    Publication date: December 30, 2010
    Inventors: Wen-bin Ho, Lee Wright, Shaojiang Deng, Eric Turtle, Lee A. Flippin